Maat Pharma (XPAR:MAAT) LT-Debt-to-Total-Asset : 0.20 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Maat Pharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Maat Pharma's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.20.

Maat Pharma's long-term debt to total assets ratio increased from Jun. 2023 (0.14) to Jun. 2024 (0.20). It may suggest that Maat Pharma is progressively becoming more dependent on debt to grow their business.

Maat Pharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for Maat Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maat Pharma LT-Debt-to-Total-Asset Chart

Maat Pharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

1.21

0.22

0.09

0.19

0.25

Maat Pharma Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial						0.13	0.19	0.14	0.25	0.20

Maat Pharma LT-Debt-to-Total-Asset Calculation

Maat Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	10.62	/	42.931
	=	0.25

Maat Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	10.064	/	50.923
	=	0.20

Maat Pharma (XPAR:MAAT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Maat Pharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Maat Pharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Maat Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maat Pharma SA (XPAR:MAAT) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

4RD:Germany

Address

70 Avenue Tony Garnier, Lyon, FRA, 69007

Website

https://www.maatpharma.com

Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.

Maat Pharma Headlines

No Headlines